Skip to main content
Equibles
CORT logo

CORT · Corcept Therapeutics Inc · Metrics

Track CORT — free

Use CORT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CORT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$115.70 +1.72 (+1.51%) At close · Sep 9
S&P 600 member Russell 1000 member Rebalance outlook locked
Market Cap
$12.32B
Shares
108.10M

CORT metrics

83 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$115.70
Market cap
$12.32B

Price action

20 metrics
Price change (1W)
+0.5%
Price change (30D)
-0.2%
Price change (3M)
+47.1%
Price change (6M)
+239.8%
Price change (YTD)
+227.5%
Price change (1Y)
+60.0%
Trailing year
Price change (5Y)
+433.6%
52-week high
$123.57
52-week low
$32.15
Change from 52-week high
-7.8%
Change from 52-week low
+254.5%
Annualized volatility
82.3%
Annualized volatility (3M)
68.4%
Beta
1.9
RSI (14D)
53.8
Price vs SMA 50
+9.0%
Price vs SMA 200
+70.1%
Avg volume (3M)
1.08M
Relative volume
1.0
Average dollar volume
$107.52M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
108.10M

Valuation

12 metrics
P / E (TTM)
271.4
Trailing earnings · reciprocal yield 0.4%
PEG ratio
11.2
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
14.8×
reciprocal yield 6.7%
P / book
17.5
reciprocal yield 5.7%
FCF yield
0.9%
TTM · current market cap
Buyback yield
0.3%
P / FCF
115.2
reciprocal yield 0.9%
P / operating cash flow
112.3
reciprocal yield 0.9%
Earnings yield
0.4%

Historical valuation

8 metrics
P / E historical average (3Y)
64.2×
reciprocal yield 1.6%
P / E historical average (5Y)
50.6×
reciprocal yield 2.0%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.3%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
98.3%
Operating margin
0.8%
Trailing 12 months
Net margin
6.6%
Gross profit (TTM)
$348.29M
Operating profit (TTM)
$6.41M
Net income (TTM)
$55.18M
Trailing 12 months
Diluted EPS (TTM)
$0.42
FCF margin
12.9%
Effective tax rate
-109.3%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$6.11

Growth

11 metrics
Revenue growth YoY
+31.7%
Year over year
Net income growth YoY
+22.3%
Revenue (TTM)
$830.81M
Trailing 12 months
EPS growth YoY
+24.1%
Shares change YoY
-1.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+23.7%
Revenue CAGR (5Y)
+16.6%
EPS CAGR (3Y)
-2.0%
EPS CAGR (5Y)
-0.7%
FCF CAGR (3Y)
+5.7%
FCF CAGR (5Y)
-1.2%

Quality

14 metrics
Return on equity
7.8%
Return on assets
6.2%
Debt / equity
—
Current ratio
2.9
EBITDA (TTM)
$8.08M
Free cash flow (TTM)
$106.92M
Quick ratio
2.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$111.04M
Total assets
$888.70M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$109.70M
Capital expenditures (TTM)
$2.78M
R&D (TTM)
$253.86M
SG&A (TTM)
$556.47M
Stock compensation (TTM)
$96.11M
R&D / revenue
30.6%
Stock compensation / revenue
11.6%

Ownership (13F)

3 metrics
13F filers
431
13F filer change QoQ
+77
Institutional ownership
78.1%

Short interest

3 metrics
Short interest
9.0%
Latest settlement · 10.5 days to cover
Days to cover
10.5d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$59.73M
Insider-sentiment score
16 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1088856 CUSIP 218352102 13F (30d) 224 filings 223 filers Visit website Investor relations